Lithium delays progression of amyotrophic lateral sclerosis

Francesco Fornai, Patrizia Longone, Luisa Cafaro, Olga Kastsiuchenka, Michela Ferrucci, Maria Laura Manca, Gloria Lazzeri, Alida Spalloni, Natascia Bellio, Paola Lenzi, Nicola Modugno, Gabriele Siciliano, Ciro Isidoro, Luigi Murri, Stefano Ruggieri, Antonio Paparelli

Research output: Contribution to journalArticle

Abstract

ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time. In a parallel study on a genetic ALS animal model, the G93A mouse, we found a marked neuroprotection by lithium, which delayed disease onset and duration and augmented the life span. These effects were concomitant with activation of autophagy and an increase in the number of the mitochondria in motor neurons and suppressed reactive astrogliosis. Again, lithium reduced the slow necrosis characterized by mitochondrial vacuolization and increased the number of neurons counted in lamina VII that were severely affected in saline-treated G93A mice. After lithium administration in G93A mice, the number of these neurons was higher even when compared with saline-treated WT. All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS.

Original languageEnglish
Pages (from-to)2052-2057
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number6
DOIs
Publication statusPublished - Feb 12 2008

Fingerprint

Amyotrophic Lateral Sclerosis
Lithium
Disease Progression
Riluzole
Neurons
Autophagy
Motor Neurons
Neurodegenerative Diseases
Mitochondria
Necrosis
Animal Models
Therapeutics

Keywords

  • Autophagy
  • Clinical study
  • G93A mice
  • Morphological analysis

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Lithium delays progression of amyotrophic lateral sclerosis. / Fornai, Francesco; Longone, Patrizia; Cafaro, Luisa; Kastsiuchenka, Olga; Ferrucci, Michela; Manca, Maria Laura; Lazzeri, Gloria; Spalloni, Alida; Bellio, Natascia; Lenzi, Paola; Modugno, Nicola; Siciliano, Gabriele; Isidoro, Ciro; Murri, Luigi; Ruggieri, Stefano; Paparelli, Antonio.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 6, 12.02.2008, p. 2052-2057.

Research output: Contribution to journalArticle

Fornai, F, Longone, P, Cafaro, L, Kastsiuchenka, O, Ferrucci, M, Manca, ML, Lazzeri, G, Spalloni, A, Bellio, N, Lenzi, P, Modugno, N, Siciliano, G, Isidoro, C, Murri, L, Ruggieri, S & Paparelli, A 2008, 'Lithium delays progression of amyotrophic lateral sclerosis', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2052-2057. https://doi.org/10.1073/pnas.0708022105
Fornai, Francesco ; Longone, Patrizia ; Cafaro, Luisa ; Kastsiuchenka, Olga ; Ferrucci, Michela ; Manca, Maria Laura ; Lazzeri, Gloria ; Spalloni, Alida ; Bellio, Natascia ; Lenzi, Paola ; Modugno, Nicola ; Siciliano, Gabriele ; Isidoro, Ciro ; Murri, Luigi ; Ruggieri, Stefano ; Paparelli, Antonio. / Lithium delays progression of amyotrophic lateral sclerosis. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 6. pp. 2052-2057.
@article{67fd1264d41c482ebe6209c8afa600cf,
title = "Lithium delays progression of amyotrophic lateral sclerosis",
abstract = "ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time. In a parallel study on a genetic ALS animal model, the G93A mouse, we found a marked neuroprotection by lithium, which delayed disease onset and duration and augmented the life span. These effects were concomitant with activation of autophagy and an increase in the number of the mitochondria in motor neurons and suppressed reactive astrogliosis. Again, lithium reduced the slow necrosis characterized by mitochondrial vacuolization and increased the number of neurons counted in lamina VII that were severely affected in saline-treated G93A mice. After lithium administration in G93A mice, the number of these neurons was higher even when compared with saline-treated WT. All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS.",
keywords = "Autophagy, Clinical study, G93A mice, Morphological analysis",
author = "Francesco Fornai and Patrizia Longone and Luisa Cafaro and Olga Kastsiuchenka and Michela Ferrucci and Manca, {Maria Laura} and Gloria Lazzeri and Alida Spalloni and Natascia Bellio and Paola Lenzi and Nicola Modugno and Gabriele Siciliano and Ciro Isidoro and Luigi Murri and Stefano Ruggieri and Antonio Paparelli",
year = "2008",
month = "2",
day = "12",
doi = "10.1073/pnas.0708022105",
language = "English",
volume = "105",
pages = "2052--2057",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "6",

}

TY - JOUR

T1 - Lithium delays progression of amyotrophic lateral sclerosis

AU - Fornai, Francesco

AU - Longone, Patrizia

AU - Cafaro, Luisa

AU - Kastsiuchenka, Olga

AU - Ferrucci, Michela

AU - Manca, Maria Laura

AU - Lazzeri, Gloria

AU - Spalloni, Alida

AU - Bellio, Natascia

AU - Lenzi, Paola

AU - Modugno, Nicola

AU - Siciliano, Gabriele

AU - Isidoro, Ciro

AU - Murri, Luigi

AU - Ruggieri, Stefano

AU - Paparelli, Antonio

PY - 2008/2/12

Y1 - 2008/2/12

N2 - ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time. In a parallel study on a genetic ALS animal model, the G93A mouse, we found a marked neuroprotection by lithium, which delayed disease onset and duration and augmented the life span. These effects were concomitant with activation of autophagy and an increase in the number of the mitochondria in motor neurons and suppressed reactive astrogliosis. Again, lithium reduced the slow necrosis characterized by mitochondrial vacuolization and increased the number of neurons counted in lamina VII that were severely affected in saline-treated G93A mice. After lithium administration in G93A mice, the number of these neurons was higher even when compared with saline-treated WT. All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS.

AB - ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time. In a parallel study on a genetic ALS animal model, the G93A mouse, we found a marked neuroprotection by lithium, which delayed disease onset and duration and augmented the life span. These effects were concomitant with activation of autophagy and an increase in the number of the mitochondria in motor neurons and suppressed reactive astrogliosis. Again, lithium reduced the slow necrosis characterized by mitochondrial vacuolization and increased the number of neurons counted in lamina VII that were severely affected in saline-treated G93A mice. After lithium administration in G93A mice, the number of these neurons was higher even when compared with saline-treated WT. All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS.

KW - Autophagy

KW - Clinical study

KW - G93A mice

KW - Morphological analysis

UR - http://www.scopus.com/inward/record.url?scp=41149124406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149124406&partnerID=8YFLogxK

U2 - 10.1073/pnas.0708022105

DO - 10.1073/pnas.0708022105

M3 - Article

C2 - 18250315

AN - SCOPUS:41149124406

VL - 105

SP - 2052

EP - 2057

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 6

ER -